Regeneron Pharmaceuticals, Inc. $REGN Holdings Raised by HighTower Advisors LLC

HighTower Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 17.1% during the 3rd quarter, Holdings Channel.com reports. The fund owned 75,679 shares of the biopharmaceutical company’s stock after purchasing an additional 11,029 shares during the quarter. HighTower Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $57,385,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Western Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $26,000. Armstrong Advisory Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 28 shares during the period. Activest Wealth Management grew its holdings in shares of Regeneron Pharmaceuticals by 780.0% in the third quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 39 shares during the last quarter. Alpine Bank Wealth Management bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $34,000. Finally, Mowery & Schoenfeld Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $29,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $945.53 on Thursday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The stock’s 50 day simple moving average is $824.37 and its two-hundred day simple moving average is $750.43. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.35. The stock has a market cap of $97.81 billion, a price-to-earnings ratio of 20.88, a PEG ratio of 1.27 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $16.51 by $3.56. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business’s revenue was up 36.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $11.83 EPS. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.30%.

Trending Headlines about Regeneron Pharmaceuticals

Here are a few of the latest headlines about REGN:

  • Positive Sentiment: The European Commission approved more flexible Libtayo dosing across six cancer indications, including an option for dosing every six weeks and shorter infusions. These changes could improve convenience for patients and infusion-center capacity, potentially supporting the oncology drug’s uptake. EU approval for flexible Libtayo dosing
  • Positive Sentiment: Barclays raised its price target on REGN to $1,075 from $917 and maintained an Overweight rating, signaling a more bullish view of the shares. Barclays price-target change
  • Neutral Sentiment: Regeneron plans to present data from 14 hematology abstracts at the December ASH meeting, including potentially pivotal Ordspono data in relapsed or refractory marginal zone lymphoma. The presentations could inform the pipeline outlook, but the data have not yet been disclosed. ASH 2026 hematology data announcement

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on REGN shares. The Goldman Sachs Group upped their price target on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a report on Friday, July 31st. Royal Bank Of Canada raised their price target on shares of Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the stock a “sector perform” rating in a report on Monday, November 2nd. Canaccord Genuity Group raised their price target on shares of Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. Finally, Wells Fargo & Company upped their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the company an “equal weight” rating in a research note on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $904.41.

Read Our Latest Analysis on Regeneron Pharmaceuticals

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, insider Andrew J. Murphy sold 4,147 shares of the firm’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. This trade represents a 7.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christine A. Poon sold 7,830 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $969.09, for a total transaction of $7,587,974.70. Following the sale, the director owned 5,219 shares in the company, valued at approximately $5,057,680.71. This trade represents a 60.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 27,028 shares of company stock valued at $25,025,950 over the last 90 days. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

See Also

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.